These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 26976984

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P, Åkesson A, Hedenfalk I, Malander S, Borgfeldt C.
    PLoS One; 2020 Nov; 15(10):e0240418. PubMed ID: 33075095
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
    Fujiwara H, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, Yamada K, Takano H, Sasaki H, Koyama K, Ochiai K.
    Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women.
    Nikolova T, Zivadinovic R, Evtimovska N, Klisarovska V, Stanojevic M, Georgievska J, Nikolova N.
    J Obstet Gynaecol Res; 2017 Dec; 43(12):1870-1879. PubMed ID: 29027715
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.
    Xu Y, Zhong R, He J, Ding R, Lin H, Deng Y, Zhou L, Li X, Jiang J, Bao Y, Luo X, Duan C.
    Clin Biochem; 2016 Jan; 49(1-2):32-40. PubMed ID: 26285075
    [Abstract] [Full Text] [Related]

  • 14. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.
    Chan KK, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Sumpaico WW.
    Gynecol Oncol; 2013 Feb; 128(2):239-44. PubMed ID: 23063998
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
    Wang Z, Tao X, Ying C.
    Dis Markers; 2019 Feb; 2019():6241743. PubMed ID: 31737130
    [Abstract] [Full Text] [Related]

  • 17. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M, Kristjansdottir B, Sundfeldt K.
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.